Charles River Laboratories International, Inc.
Location
Massachusetts
Founded
1947-02-28
Website
Risk Signals
1058 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Commercial Physical and Biological Research, Testing Laboratories), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Charles River Laboratories International, Inc.
Live alerts from global media, monitored by Business Radar
2025-04-23 (nature.com)
Treatment of acute myeloid leukemia models by targeting a cell surface RNA-binding protein | Biotechnology
Immunotherapies for acute myeloid leukemia (AML) and other cancers are limited by a lack of tumor-specific targets. Here we discover that RNA-binding proteins and glycosylated RNAs (glycoRNAs) form precisely organized nanodomains on cancer cell surfaces. We characterize nucleophosmin (NPM1) as an abundant cell surface protein (csNPM1) on a variety of tumor types. With a focus on AML, we observe csNPM1 on blasts and leukemic stem cells but not on normal hematopoietic stem cells. We develop a monoclonal antibody to target csNPM1, which exhibits robust anti-tumor activity in multiple syngeneic and xenograft models of AML, including patient-derived xenografts, without observable toxicity. We find that csNPM1 is expressed in a mutation-agnostic manner on primary AML cells and may therefore offer a general strategy for detecting and treating AML. Surface profiling and in vivo work also demonstrate csNPM1 as a target on solid tumors.
Read more
2025-04-23 (abril.com.br)
TUPY CASE: CVM Minority Frusta and maintains assembly to exchange council
Manager Charles River, minority shareholder of the auto parts manufacturer, accuses Bndespar and predicted from being controllers of the company
Read more
2025-04-22 (biospace.com)
Charles River Leverages Advanced Technology to Expedite Oncology Drug Discovery and Development -
Utilizing a fully human platform, the company expands in vitro assays to develop a more translational offering
Read more
2025-04-22 (ddw-online.com)
Enhancing rapid microbiology QC in cell & gene therapy - Drug Discovery World (DDW)
Dr Jeff Domsic, Product Manager Charles River Laboratories, discusses ATP-bioluminescence testing aligned with new regulatory guidelines.
Read more
2025-04-21 (marketwatch.com)
Charles River Laboratories International Inc. stock underperforms Monday when compared to competitors
slid 3.19% to $102.67 Monday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index.
Read more
2025-04-21 (directorstalkinterviews.com)
Charles River Laboratories (CRL) Stock Analysis: Promising Upside Despite Recent Challenges
Charles River Laboratories (CRL) Stock Analysis: Promising Upside Despite Recent Challenges
Read more
2025-04-17 (openpr.com)
Genetic Toxicology Testing Market to Witness Massive Growth by 2032 | Thermo Fisher Scientific, Inc., WuXi AppTec, Charles River Laboratories International
Press release - Coherent Market Insights - Genetic Toxicology Testing Market to Witness Massive Growth by 2032 | Thermo Fisher Scientific, Inc., WuXi AppTec, Charles River Laboratories International - published on openPR.com
Read more
2025-04-15 (theretirementgroup.com)
Charles River Laboratories International Hostage Data: Ransomware and Protecting Your Digital Information
Charles River Laboratories International employees should be aware of the increased risks ransomware poses to critical infrastructure, exemplified by the Colonial Pipeline attack, which underscores the importance of robust cybersecurity measures. As Charles River Laboratories International navigates these challenges, it's crucial for its workforce to stay informed on protecting company and personal data from such threats.
Read more
2025-04-15 (biospace.com)
Charles River Laboratories Schedules First-Quarter 2025 Earnings Release and Conference Call -
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2025 financial results on Wednesday, May 7th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, May 7th, at 9:00 a.m. ET.
Read more